Is it safe to stop taking Dacomitinib for a few days when the side effects are severe?

Dacomitinib (also known as dacomitinib) is an oral EGFR inhibitor mainly used to treat EGFR mutation-positive non-small cell lung cancer. Although this drug performs well in prolonging progression-free survival, its strong inhibitory effect also brings a certain degree of side effects, such as rash, diarrhea, oral mucositis, and decreased appetite. In clinical application, patients often need to adjust their medication strategies due to side effects that affect their quality of life.

When patients experience significant side effects while taking dacomitinib, doctors usually consider temporarily discontinuing the drug or reducing the dose depending on the severity. Generally speaking, if the side effects are moderate (such as persistent diarrhea or severe rash), the medication can be stopped for 2-5 days under the guidance of a doctor, and symptomatic treatment can be provided, such as using antidiarrheal drugs, antibiotics, or topical medications to relieve symptoms. In most cases, side effects can be significantly improved after a brief discontinuation of medication, at which point resumption of treatment can be considered.

However, whether the drug can be discontinued and the length of the discontinuation time should be evaluated by a professional doctor, and patients are not recommended to interrupt treatment on their own. Blindly stopping medication or interrupting medication for a long time may lead to disease rebound or an increased risk of drug resistance. Especially for patients whose disease control is relatively stable, continued treatment is very important. Therefore, patients should proactively report side effects to their doctors and strictly follow the doctor's instructions to make adjustments instead of stopping the medication on their own.

To sum up, dacomitinib can be briefly discontinued for a few days under the guidance of a doctor when side effects occur, and is mostly safe. However, an adjustment plan must be developed based on specific symptoms and individual responses. During treatment, patients should closely monitor their physical reactions, communicate symptoms of discomfort in a timely manner, and avoid unauthorized changes to their medication plans to ensure treatment effects and medication safety.

Reference materials:https://www.drugs.com